Health Aff (Millwood). 2001 Sep-Oct;20(5):101-17.

The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer.

Source

Harvard School of Public Health in Boston, USA.

Abstract

In the 1990s more than 41,000 patients underwent high-dose chemotherapy plus autologous bone marrow transplant (HDC-ABMT) for breast cancer, despite a paucity of clinical evidence of its efficacy. Most health plans reluctantly agreed to cover the treatment in response to intensive political lobbying and the threat of litigation. The results of five recent major randomized trials showed that HDC-ABMT offers no advantage over standard-dose treatment for breast cancer. Our experience with HDC-ABMT coverage cautions against allowing politics to overwhelm science in the area of evaluating experimental procedures, and against relying on the courts as a means of resolving disagreements about coverage of these interventions.

PMID:: 11558695; [PubMed - indexed for MEDLINE]

Free full text

MeSH Terms, Substances

MeSH Terms

Substances

Antineoplastic Agents

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Supplemental Content

Save items

Related citations in PubMed

Litigating the science of breast cancer treatment. [J Health Polit Policy Law. 2007]
Litigating the science of breast cancer treatment.
Jacobson PD, Rettig RA, Aubry WM. J Health Polit Policy Law. 2007 Oct; 32(5):785-818.
New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer. [South Med J. 1998]
New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer.
Lucey C, Westphal JR. South Med J. 1998 Feb; 91(2):196-201.
Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. [Psychooncology. 1999]
Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.
Winer EP, Lindley C, Hardee M, Sawyer WT, Brunatti C, Borstelmann NA, Peters W. Psychooncology. 1999 Mar-Apr; 8(2):167-76.
Review High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. [J Clin Oncol. 1992]
Review High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer.
Eddy DM. J Clin Oncol. 1992 Apr; 10(4):657-70.
Review High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out. [Important Adv Oncol. 1995]
Review High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out.
Smith GA, Henderson IC. Important Adv Oncol. 1995; :201-14.

See reviews... See all...

Cited by 3 PubMed Central articles

Review Ethical issues in autologous stem cell transplantation (ASCT) in advanced breast cancer: a systematic literature review. [BMC Med Ethics. 2011]
Review Ethical issues in autologous stem cell transplantation (ASCT) in advanced breast cancer: a systematic literature review.
Droste S, Herrmann-Frank A, Scheibler F, Krones T. BMC Med Ethics. 2011 Apr 15; 12:6. Epub 2011 Apr 15.
Marketing, media, wishful thinking, and conflicts of interest: inflating the value of new medical technology. [Perm J. 2009]
Marketing, media, wishful thinking, and conflicts of interest: inflating the value of new medical technology.
Deyo RA. Perm J. 2009 Spring; 13(2):71-6.
Screening in the dark: ethical considerations of providing screening tests to individuals when evidence is insufficient to support screening populations. [Am J Bioeth. 2009]
Screening in the dark: ethical considerations of providing screening tests to individuals when evidence is insufficient to support screening populations.
Burger IM, Kass NE. Am J Bioeth. 2009 Apr; 9(4):3-14.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

The controversy over high-dose chemotherapy with autologous bone marrow transpla...
The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer.
Health Aff (Millwood). 2001 Sep-Oct ;20(5):101-17.

PubMed
Final report on the safety assessment of Calendula officinalis extract and Calen...
Final report on the safety assessment of Calendula officinalis extract and Calendula officinalis.
Int J Toxicol. 2001 ;20 Suppl 2:13-20.

PubMed
Cognitive function after HRT.
Cognitive function after HRT.
Lancet. 2001 Feb 24 ;357(9256):641.

PubMed
Bupropion for weight loss: an investigation of efficacy and tolerability in over...
Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
Obes Res. 2001 Sep ;9(9):544-51.

PubMed
Estimation of energy expenditure from physical activity measures: determinants o...
Estimation of energy expenditure from physical activity measures: determinants of accuracy.
Obes Res. 2001 Sep ;9(9):517-25.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: